Activated Protein C Improves Survival in Severe Sepsis Patients with Elevated Troponin

Overview

Journal Intensive Care Med

Specialty Critical Care

Date 2007 Aug 9

PMID 17684722

Citations 14

Authors

Jijo John

Ahmed Awab

Derek Norman

Tarek Dernaika

Gary T Kinasewitz

Affiliations

Soon will be listed here.

Abstract

Objective: Multiple studies in sepsis have demonstrated that elevated troponin is associated with poor outcome. The elevated troponin in this situation is thought to be secondary to microthrombi. We hypothesized that recombinant human activated protein C (APC) treatment would improve outcomes in severe sepsis patients who have elevated troponin.

Methods: Patients with severe sepsis by consensus criteria in a university ICU were divided into a troponin elevated group (cTnI+) and a normal troponin (cTnI(-)) group. Outcome was compared using Fisher's exact test. APACHE[Symbol: see text]II and MODS were calculated by standard methods.

Patients: We identified 105 patients with severe sepsis and troponin measured, of which 48 (46%) were in the cTnI+ group. The two groups were similar in terms of age and other comorbid conditions.

Results: APACHE II (28+/-8 vs. 25+/-8) was slightly higher and MODS (11+/-4 vs. 9+/-3) was significantly higher in the cTnI+ group. Mortality was 52% (25/48) in cTnI+ group and 30% (17/57) in cTnI(-) group. Mortality was 30% in cTnI+ patients treated with APC and 72% in untreated cTnI+ patients.

Conclusions: Patients with severe sepsis who have elevated troponin have increased mortality. In patients with severe sepsis who have elevated troponin, treatment with APC improves outcome. Further study is needed to determine whether troponin can serve as a simple, readily available marker to identify which patients with severe sepsis will benefit from APC.

Citing Articles

Association between D-dimer-to-albumin ratio and 28-days all-cause mortality in patients with sepsis.

Lu J, Fang W, Lei Y, Yang J Sci Rep. 2024; 14(1):28361.

PMID: 39550487 PMC: 11569141. DOI: 10.1038/s41598-024-79911-0.

Towards personalized medicine: a scoping review of immunotherapy in sepsis.

Slim M, van Mourik N, Bakkerus L, Fuller K, Acharya L, Giannidis T Crit Care. 2024; 28(1):183.

PMID: 38807151 PMC: 11134696. DOI: 10.1186/s13054-024-04964-6.

Cardiac troponin as a prognosticator of mortality in patients with sepsis: A systematic review and meta-analysis.

Zheng P, Wang X, Guo T, Gao W, Huang Q, Yang J Immun Inflamm Dis. 2023; 11(9):e1014.

PMID: 37773717 PMC: 10515504. DOI: 10.1002/iid3.1014.

Life-threatening complications of streptococcal sepsis: a PICU contemporary series.

Piastra M, Ferrari V, Picconi E, Morena T, Pezza L, De Rosa G J Anesth Analg Crit Care. 2023; 1(1):24.

PMID: 37386530 PMC: 8669399. DOI: 10.1186/s44158-021-00028-1.

Cardiovascular Factors Associated with Septic Shock Mortality Risks.

Arnautovic J, Mazhar A, Souther B, Mikhijan G, Boura J, Huda N Spartan Med Res J. 2021; 3(1):6516.

PMID: 33655132 PMC: 7746094.

References

Mehta N, Khan I, Gupta V, Jani K, Gowda R, Smith P . Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock. Int J Cardiol. 2004; 95(1):13-7. DOI: 10.1016/j.ijcard.2003.02.005. View

Wesley Ely E, Laterre P, Angus D, Helterbrand J, Levy H, Dhainaut J . Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med. 2003; 31(1):12-9. DOI: 10.1097/00003246-200301000-00002. View

Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo J . Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 1996; 183(3):949-58. PMC: 2192364. DOI: 10.1084/jem.183.3.949. View

Taylor Jr F, Toh C, Hoots W, Wada H, Levi M . Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2002; 86(5):1327-30. View

Wilder R, Lafyatis R, Roberts A, Case J, Kumkumian G, Sano H . Transforming growth factor-beta in rheumatoid arthritis. Ann N Y Acad Sci. 1990; 593:197-207. DOI: 10.1111/j.1749-6632.1990.tb16112.x. View

Levy M, Fink M, Marshall J, Abraham E, Angus D, Cook D . 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31(4):1250-6. DOI: 10.1097/01.CCM.0000050454.01978.3B. View

Arlati S, Brenna S, PRENCIPE L, Marocchi A, Casella G, Lanzani M . Myocardial necrosis in ICU patients with acute non-cardiac disease: a prospective study. Intensive Care Med. 2000; 26(1):31-7. DOI: 10.1007/s001340050008. View

Esmon C . The protein C pathway. Chest. 2003; 124(3 Suppl):26S-32S. DOI: 10.1378/chest.124.3_suppl.26s. View

Marshall J, Cook D, Christou N, Bernard G, Sprung C, Sibbald W . Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995; 23(10):1638-52. DOI: 10.1097/00003246-199510000-00007. View

10.

Ammann P, Maggiorini M, Bertel O, Haenseler E, Joller-Jemelka H, Oechslin E . Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol. 2003; 41(11):2004-9. DOI: 10.1016/s0735-1097(03)00421-2. View

11.

Ammann P, Fehr T, Minder E, Gunter C, Bertel O . Elevation of troponin I in sepsis and septic shock. Intensive Care Med. 2001; 27(6):965-9. DOI: 10.1007/s001340100920. View

12.

Beranek J . Cardiomyocyte apoptosis contributes to the pathology of the septic shock heart. Intensive Care Med. 2002; 28(2):218; author reply 219. DOI: 10.1007/s00134-001-1181-6. View

13.

van Bockel E, Tulleken J, Muller Kobold A, Ligtenberg J, van der Werf T, Spanjersberg R . Cardiac troponin I release and cytokine response during experimental human endotoxaemia. Intensive Care Med. 2003; 29(9):1598-600. DOI: 10.1007/s00134-003-1893-x. View

14.

Piper H, Schwartz P, Spahr R, Hutter J, Spieckermann P . Early enzyme release from myocardial cells is not due to irreversible cell damage. J Mol Cell Cardiol. 1984; 16(4):385-8. DOI: 10.1016/s0022-2828(84)80609-4. View

15.

Bajzar L, Nesheim M, Tracy P . The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood. 1996; 88(6):2093-100. View

16.

Yan S, Helterbrand J, Hartman D, Wright T, Bernard G . Low levels of protein C are associated with poor outcome in severe sepsis. Chest. 2001; 120(3):915-22. DOI: 10.1378/chest.120.3.915. View

17.

Ammann P, Pfisterer M, Fehr T, Rickli H . Raised cardiac troponins. BMJ. 2004; 328(7447):1028-9. PMC: 403831. DOI: 10.1136/bmj.328.7447.1028. View

18.

Alpert J, Thygesen K, Antman E, Bassand J . Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000; 36(3):959-69. DOI: 10.1016/s0735-1097(00)00804-4. View

19.

Pathan N, Hemingway C, Alizadeh A, Stephens A, Boldrick J, Oragui E . Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet. 2004; 363(9404):203-9. DOI: 10.1016/S0140-6736(03)15326-3. View

20.

Abraham E, Laterre P, Garg R, Levy H, Talwar D, Trzaskoma B . Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005; 353(13):1332-41. DOI: 10.1056/NEJMoa050935. View